NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Modernising Medical Microbiology and Big Infection Diagnostics > Antiviral drug could be given to more chronic hepatitis B patients, study finds

Antiviral drug could be given to more chronic hepatitis B patients, study finds

14 July 2021 · Listed under Modernising Medical Microbiology and Big Infection Diagnostics, Translational Data Science

A study by Oxford University researchers has found that the antiviral drug TDF may benefit a greater number of patients with chronic hepatitis B virus, and that those who are untreated may be at greater risk of liver inflammation and fibrosis.

Microscopic image of the hepatitis B virus
Hepatitis B virus (Sanofi Pasteur via Flickr)

The research was carried out under the auspices of the National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC), established in 2014 to make routinely collected clinical data available for translational research in selected therapeutic areas across multiple sites. The NIHR HIC viral hepatitis theme is led by Oxford University Hospitals NHS Foundation Trust and the University of Oxford, through the NIHR Oxford Biomedical Research Centre (BRC).

The paper was published in the open access journal BMC Infectious Diseases.

Current clinical guidelines recommend treating chronic hepatitis B virus (HBV) infection with TDF (tenofovir disoproxil fumarate) in a minority of cases. But until now, there were relatively scarce data on the evolution or progression of liver inflammation and fibrosis in cases of chronic HBV (CHB) that did not meet treatment criteria.

Assessing data from outpatient clinics between 2005 and 2018, the Oxford BRC researchers set out to assess the impact of TDF on liver disease, and the risk of renal impairment in treated CHB patients, compared to patients who did not receive the drug.

The ethnically diverse cohort that was studied included 206 adult patients, 60 on TDF and 146 not receiving the drug.

As expected, viral load and ALT (Alanine transaminase – an enzyme that indicates liver damage when levels are high) declined significantly over time in patients treated with TDF. Elastography scores – an indication of fibrosis – also normalised during treatment.

Some seven per cent of intreated patients had a progression of fibrosis, while the researchers found no evidence of difference in incidence of renal impairment between the two groups.

One of the authors of the paper, Dr Philippa Matthews, Associate Professor at the University of Oxford’s Nuffield Department of Medicine, said: “This study shows the clear benefits of TDF therapy in a diverse CHB population, even among those patients with only mild or moderate liver disease.

“These benefits may be relevant to a wider pool of the untreated CHB population, given the lack of difference in renal impairment observed in the two groups. Larger population studies, over longer periods of follow-up, are urgently needed to provide the evidence to underpin expanded treatment guidelines.”

← “Modest” increase in heart attack hospitalisation rates after years of decline
COVID-19 risk prediction tool wins national award →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre